Ga-68 Generator Elution Readiness for PET Imaging Sites
Ga-68 generators have moved diagnostic PET radiopharmaceuticals from the cyclotron-only model into the hospital and stand-alone imaging-center model.
In Short
- Three commercial Ga-68 generators dominate: Eckert & Ziegler GalliaPharm (HCl elution, EU GMP grade), IRE ELiT Galli Eo (HCl, EU GMP), and Curium Galliad.
- Pre-elution: hot-cell verification, dose calibrator constancy, automated synthesizer cassette change, precursor reconstitution (DOTATATE or PSMA-11 cold kit).
- Ge-68 breakthrough (parent isotope contamination of the daughter eluate) is the highest-risk QC parameter — a Ge-68 contaminated dose delivers the long-lived parent…
With a 68-minute half-life on Ga-68 and a 270-day half-life on the Ge-68 parent, a single generator supports 1–2 doses per elution and 2–3 elutions per day for up to 12 months. Ga-68-DOTATATE (NETSPOT, approved 2016) for neuroendocrine tumors and Ga-68-PSMA-11 (approved 2020) for prostate cancer are the volume drivers. This guide covers the operating model: generator qualification, elution discipline, breakthrough testing, automated labeling, and the controls that imaging-center inspectors look for.
Generator Landscape and Qualification
More on generator Landscape and Qualification
Site qualification covers receipt-inspection, elution-yield verification on first elution, and breakthrough testing on every elution thereafter. Generator change-out at end-of-life (EOL) is a formal procedure with disposal documentation under 10 CFR 20 / EU radiation-protection rules.
Elution operations — the practical cycle
Pre-elution: hot-cell verification, dose calibrator constancy, automated synthesizer cassette change, precursor reconstitution (DOTATATE or PSMA-11 cold kit). Elution: 0.1 M HCl pumped through the generator into the synthesizer module; typical eluate volume 5–10 mL, activity 800–1850 MBq depending on generator age.
More on elution operations — the practical cycle
Labeling: heated reaction at 95°C, solid-phase purification, sterile filtration. End-to-end time from elution to release ~30–45 minutes.
Breakthrough testing — the safety-critical control
Ge-68 breakthrough (parent isotope contamination of the daughter eluate) is the highest-risk QC parameter — a Ge-68 contaminated dose delivers the long-lived parent to the patient. Specification: Ge-68 breakthrough <0.001% of total activity (1 in 100,000).
More on breakthrough testing — the safety-critical control
Test method: hold a small aliquot of eluate for ≥ 48 hours to let Ga-68 decay completely, then measure residual Ge-68 by gamma spectroscopy. The 48-hour wait means breakthrough is verified retrospectively, not pre-release — every elution is released on the validated assumption of breakthrough conformance based on the generator's qualification history.
Release model and conditional release
Release criteria: pH, appearance, radiochemical purity (HPLC and ITLC, ≥91% bound), radionuclidic identity (511 keV photopeak, half-life check), pyrogen / endotoxin (rapid LAL recommended given the 68-min half-life — a kinetic chromogenic assay returns in 15 minutes). Sterility is by membrane filtration at 0.22 µm; the post-release sterility test runs 14 days.
More on release model and conditional release
This is the same conditional-release model as 21 CFR 212.70(f) — the 68-min Ga-68 half-life makes any other model physically impossible.
Inspection Patterns
FDA, EMA, and state-board inspectors concentrate on: breakthrough trend records over the generator's life, automated-synthesizer cassette lot traceability, environmental monitoring of the hot cell and prep room, dose-calibrator linearity for the activity range used (especially at low activities late in generator life), and patient-specific dispense records. The most common 483 / deficiency in 2023–2025 is incomplete or generic environmental monitoring of the hot-cell critical zone.
Questions
How many doses per generator per day are realistic?
A new generator (week 1–8) supports 2–3 elutions per day with 2 patient doses per elution. By month 6 yields drop and most sites elute once per day for 1 dose. End-of-life (typically 9–12 months) is driven by yield falling below clinical viability, not Ge-68 exhaustion — Ge-68 half-life of 270 days means there is always some Ga-68 available.
Can we re-use the eluate for two patients?
If both patients are scheduled within ~60 minutes of release and the dispensed activity is decay-corrected, yes — the labeling product is split into two patient-specific dispenses. Most sites schedule patients in pairs to optimize generator economics.
Is Ga-68 generator operation 21 CFR 212 or 211?
Neither, generally. NETSPOT and PSMA-11 manufacture under 21 CFR 212 is performed by the kit / generator manufacturer. The imaging site is doing prescription-pharmacy compounding under USP <825> or, in some configurations, distributing under an approved NDA. The boundary is set by state pharmacy law and whether interstate shipment occurs.
What happens if breakthrough fails the retrospective test?
Patient-notification protocol, deviation investigation, generator quarantine, regulatory notification. Because the test is retrospective, this is a known residual risk and the generator's design and qualification history are the primary controls.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
Keep reading
Radiopharmaceutical Manufacturing Readiness: Runs and Dispatch
10 CFR Part 35 Medical Use: Written Directives, Dosage Records and Medical Events
21 CFR 212 PET Drug cGMP Readiness: Production Evidence Guide
Radiopharmaceutical Release Before All Tests Finish: PET Evidence- Lu-177 Radioligand Production in the US: Parts 210/211, Not Part 212, and NRC Licensing
USP <825> Radiopharmaceutical Preparation and Compounding: Readiness Guide